Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
MEP39208A - USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION - Google Patents
[go: Go Back, main page]

MEP39208A - USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION - Google Patents

USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION

Info

Publication number
MEP39208A
MEP39208A MEP-392/08A MEP39208A MEP39208A ME P39208 A MEP39208 A ME P39208A ME P39208 A MEP39208 A ME P39208A ME P39208 A MEP39208 A ME P39208A
Authority
ME
Montenegro
Prior art keywords
hcg
ovarian hyperstimulation
controlled ovarian
controlled
hyperstimulation
Prior art date
Application number
MEP-392/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Yves Menezo
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of MEP39208A publication Critical patent/MEP39208A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MEP-392/08A 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION MEP39208A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01307757 2001-09-12
PCT/GB2002/004158 WO2003022302A2 (en) 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION

Publications (1)

Publication Number Publication Date
MEP39208A true MEP39208A (en) 2011-02-10

Family

ID=8182261

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-392/08A MEP39208A (en) 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION

Country Status (19)

Country Link
US (1) US7405197B2 (sr)
EP (1) EP1425032A2 (sr)
JP (1) JP2005501918A (sr)
KR (1) KR20040032954A (sr)
CN (1) CN100536912C (sr)
AR (1) AR036592A1 (sr)
BR (1) BR0212429A (sr)
CA (1) CA2457849A1 (sr)
EA (1) EA009330B1 (sr)
HR (1) HRP20040087A2 (sr)
IL (1) IL160780A0 (sr)
ME (1) MEP39208A (sr)
MX (1) MXPA04002256A (sr)
NO (1) NO20040991L (sr)
PL (1) PL369098A1 (sr)
RS (1) RS21004A (sr)
UA (1) UA82650C2 (sr)
WO (1) WO2003022302A2 (sr)
ZA (1) ZA200400835B (sr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003212569A1 (en) * 2003-02-07 2004-08-30 Ambros Valentin Huber Use of human chorionic gonadotropin in the treatment in the treatment of symptoms caused by endometriosis
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US20150273020A1 (en) * 2007-05-11 2015-10-01 Lori R. Bernstein Hormone Normalization Therapy and Uses Therefor
ATE555721T1 (de) * 2009-04-23 2012-05-15 Hoffmann La Roche Verfahren und gerät zur ermittlung von empfehlungen für wirkstoffdosierungen anhand von messserien zumindest eines physiologischen parameters eines patienten
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
PL2691119T3 (pl) 2011-03-31 2019-01-31 Ferring B.V. Preparat farmaceutyczny
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
US20120265129A1 (en) * 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
BR112014001274A2 (pt) 2011-07-18 2017-04-18 Arts Biologics As composto de hormônio luteinizante, e, composição farmacêutica
US10271876B2 (en) 2011-11-23 2019-04-30 Mezadata Medical Ip Holding Llc Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
WO2014063071A1 (en) 2012-10-18 2014-04-24 Neuralight Hd, Llc Treatment of depression and ptsd
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
UA127283C2 (uk) 2016-07-21 2023-07-12 Обсева С.А. Спосіб застосування антагоніста окситоцину для сприяння імплантації ембріона і запобігання викидню
WO2018044789A1 (en) 2016-08-29 2018-03-08 Progena, Inc. Autologous somatic stem cell therapy, method of controllable preparation of therapeutic composition and procedure of adaptive treatment of ivf patient
RU2646578C1 (ru) * 2017-02-13 2018-03-05 Федеральное государственное бюджетное военное образовательное учреждение высшего образования Военно-медицинская академия им. С.М. Кирова Министерства обороны Российской Федерации (ВМедА) Способ повышения эффективности имплантации эмбриона в естественном цикле зачатия и в протоколах вспомогательных репродуктивных технологий
CN109431647B (zh) * 2018-09-20 2020-10-30 华中农业大学 一种杂交水牛同期发情-定时输精的处理方法
US20220323410A1 (en) 2019-09-03 2022-10-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
TW202210096A (zh) * 2020-05-29 2022-03-16 荷蘭商菲林公司 治療不育症之方法
WO2026018221A1 (en) 2024-07-18 2026-01-22 ReproNovo SA Crystalline compositions for improving embryo implantation and methods of using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US5705478A (en) * 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
ATE302018T1 (de) 1997-06-20 2005-09-15 Akzo Nobel Nv Gonadotropin releasing hormon antagonist
ZA987497B (en) * 1997-09-08 1999-02-23 Akzo Nobel Nv Expression of gonadotropins in dictyostelium
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
CN1353617A (zh) * 1999-02-24 2002-06-12 诺沃挪第克公司 不孕症的治疗
PT1176976E (pt) * 1999-05-07 2006-11-30 Applied Research Systems Utilização de lh administrada na fase folicular média e tardia para o tratamento de mulheres anovulatórias.
CA2397680A1 (en) * 2000-01-27 2001-08-02 Applied Research Systems Ars Holding N.V. Use of fsh for treating infertility

Also Published As

Publication number Publication date
US20050065069A1 (en) 2005-03-24
NO20040991L (no) 2004-03-08
CN1553808A (zh) 2004-12-08
WO2003022302A3 (en) 2003-12-18
RS21004A (sr) 2006-12-15
US7405197B2 (en) 2008-07-29
AR036592A1 (es) 2004-09-22
EP1425032A2 (en) 2004-06-09
EA200400427A1 (ru) 2004-08-26
PL369098A1 (en) 2005-04-18
UA82650C2 (uk) 2008-05-12
IL160780A0 (en) 2004-08-31
CA2457849A1 (en) 2003-03-20
ZA200400835B (en) 2005-04-26
MXPA04002256A (es) 2004-07-23
KR20040032954A (ko) 2004-04-17
BR0212429A (pt) 2004-10-26
EA009330B1 (ru) 2007-12-28
CN100536912C (zh) 2009-09-09
JP2005501918A (ja) 2005-01-20
WO2003022302A2 (en) 2003-03-20
HK1067867A1 (zh) 2005-04-22
HRP20040087A2 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
MEP39208A (en) USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
SE0100901D0 (sv) New composition
MXPA02004666A (es) Gelatinas recombinantes.
BR0215405A (pt) Composições e processos de uso de collajolie
DK1255826T3 (da) Automatisering af proteindesign for proteinbiblioteker
NO20031471L (no) Glykoformer av faktor VII
BR0317715A (pt) Composições e processos de uso de collajolie
ATE337775T1 (de) Strukturen und zusammensetzungen zur erhöhung der stabilität von aktiven peroxiden
IL156774A0 (en) Inhibitors of cruzipain and other cysteine proteases
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
CY1108446T1 (el) Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αντιμετωπιση αποπληξιας
MEP38708A (en) Use of hcg and lh in controlled ovarian hyperstimulation
AU6276301A (en) A variable region of the monoclonal antibody against the hbv s-surface antigen and a gene encoding the same
ATE430403T1 (de) Synchronisierter gesteuerter oszillationsmodulator
DE60219337D1 (de) Gewebe
DK1274426T3 (da) Anvendelse af thioamidoxazolidinoner til behandling af knogleresorption og osteoporose
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
DK1224166T3 (da) Fremgangsmåde til fremstilling af N-(4,5-bis-methansulfonyl-2-methyl-benzoyl)-guanidin-hydrochlorid
DK1390022T3 (da) Anvendelse af 4-(2-fluorphenyl)-6-methyl-2-(1-piperazinyl)thieno (2,3-D)pyrimidin til behandling af smerte
DK1368478T3 (da) Polypeptid, der fremkalder HIV-neutraliserende antistoffer
MXPA04004526A (es) N-metil-homocisteinas, su uso y metodo para su produccion.
WO2002057248A3 (en) Inhibitors of cruzipain and other cysteine proteases
DE60239829D1 (de) Kombinieren von schmalbandanwendungen mit breitbandtransport
WO2002042413A3 (en) Methods and compositions involved in groucho-mediated differentiation
FI4950U1 (fi) Keraaminen tiili